A Minimalist Pathogen‐Like Sugar Nanovaccine for Enhanced Cancer Immunotherapy
Miao Y, Niu L, Lv X, Zhang Q, Xiao Z, Ji Z, Chen L, Liu Y, Liu N, Zhu J, Yang Y, Chen Q. A Minimalist Pathogen‐Like Sugar Nanovaccine for Enhanced Cancer Immunotherapy. Advanced Materials 2024, 36: e2410715. PMID: 39210649, DOI: 10.1002/adma.202410715.Peer-Reviewed Original ResearchCancer immunotherapyMaturation of antigen-presenting cellsVaccine carriersImmune checkpoint blockade therapyAntigen-specific immune responsesInhibition of tumor growthCheckpoint blockade therapyEnhanced cancer immunotherapyAntigen-presenting cellsVaccine delivery technologiesB16-OVABlockade therapyImmune activationTumor modelTumor growthAntigen loadNanovaccineImmune responseMeticulous screeningAntigenic peptidesImmunostimulatory characteristicsChain ratioDelivery technologiesImmunotherapyIn vivoOvercoming melanin interference in melanocyte photodynamic therapy with a pyrene-derived two-photon photosensitizer
Juvekar V, Cao Y, Koh C, Lee D, Kwak S, Kim S, Park T, Park S, Liu Z, Kim H. Overcoming melanin interference in melanocyte photodynamic therapy with a pyrene-derived two-photon photosensitizer. Chemical Engineering Journal 2024, 493: 152796. DOI: 10.1016/j.cej.2024.152796.Peer-Reviewed Original ResearchPhotodynamic therapyPhotodynamic therapy efficacyPlasma membrane of melanoma cellsMelanoma cellsInhibition of tumor growthReactive oxygen speciesConventional photodynamic therapyTails of miceTreatment of skin diseasesTumor modelTreat melanomaTumor growthMelanin contentMulticellular tumor spheroidsSkin cancerMelanomaVisible light irradiationPDT efficacySkin diseasesMelanin interferenceVisible light excitationBroad absorption spectraChlorin e6ROS generation efficiencyTP-PDTNanoparticle Retinoic Acid-Inducible Gene I Agonist for Cancer Immunotherapy
Wang-Bishop L, Wehbe M, Pastora L, Yang J, Kimmel B, Garland K, Becker K, Carson C, Roth E, Gibson-Corley K, Ulkoski D, Krishnamurthy V, Fedorova O, Richmond A, Pyle A, Wilson J. Nanoparticle Retinoic Acid-Inducible Gene I Agonist for Cancer Immunotherapy. ACS Nano 2024, 18: 11631-11643. PMID: 38652829, PMCID: PMC11080455, DOI: 10.1021/acsnano.3c06225.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsTumor microenvironmentLipid nanoparticlesBreast cancerResponse to ICIResponse to immune checkpoint inhibitorsInfiltration of CD8<sup>+</sup>Models of triple-negative breast cancerCD4<sup>+</sup> T cellsInhibition of tumor growthTriple-negative breast cancerRIG-IIonizable lipid nanoparticlesLung metastatic burdenIncrease tumor immunogenicityBreast tumor microenvironmentSignaling in vitroACTLA-4Immunogenic melanomaCheckpoint inhibitorsTumor immunogenicityImmunotherapeutic modalitiesCancer immunotherapyMetastatic burdenAPD-1
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply